These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9208116)

  • 1. Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients.
    Schulze R; Schulze M; Wischnik A; Ehnle S; Doukas K; Behr W; Ehret W; Schlimok G
    Bone Marrow Transplant; 1997 Jun; 19(12):1223-8. PubMed ID: 9208116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
    Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
    Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.
    Vredenburgh JJ; Silva O; Broadwater G; Berry D; DeSombre K; Tyer C; Petros WP; Peters WP; Bast RC
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):91-7. PubMed ID: 9267669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer.
    Hohaus S; Wallwiener D; Martin S; Voso MT; Huober J; Fersis N; Bastert G; Haas R
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):7-11; discussion 45-8. PubMed ID: 9578056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [CBDCA, etoposide and epirubicin high-dose combination chemotherapy supported by peripheral blood stem cell transplantation (PBSCT) in metastatic breast cancer].
    Suwata J; Takada S; Murata N; Ishizuka N; Idezuki Y; Kobayashi M
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):83-8. PubMed ID: 9987502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Myeloablative chemotherapy with autologous bone marrow and/or peripheral blood stem cell transplantation in children with high-risk solid tumor].
    Endo M; Tanosaki R
    Gan To Kagaku Ryoho; 1995 Oct; 22(12):1762-70. PubMed ID: 7574807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells.
    Weaver CH; Moss T; Schwartzberg LS; Zhen B; West J; Rhinehart S; Campos L; Beeker T; Lautersztain L; Messino M; Buckner CD
    Bone Marrow Transplant; 1998 Jun; 21(11):1117-24. PubMed ID: 9645574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early intensive and myeloablative adjuvant chemotherapy in women with high-risk breast cancer.
    Wörmann B; Meden H; Riggert J; Humpe A; Wulf G; Koch B; Köhler M; Kuhn W; Hiddemann W
    Anticancer Res; 1998; 18(3C):2237-41. PubMed ID: 9703793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
    Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
    Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
    Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
    Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous bone marrow support and bone disease in metastatic breast cancer.
    Nabholtz JM; al-Tweigeri T; Jacquelin N; Venner PM
    Can J Oncol; 1995 Jul; 5(2):369-75. PubMed ID: 8853509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
    Shi Y; Pan F; Han X
    Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer.
    Ross AA; Miller GW; Moss TJ; Kahn DG; Warner NE; Sweet DL; Louie KG; Schneidermann E; Pecora AL; Meagher RC
    Bone Marrow Transplant; 1995 Jun; 15(6):929-33. PubMed ID: 7581093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation.
    Solano C; Badia B; Lluch A; Marugan I; Benet I; Arbona C; Prosper F; García-Conde J
    Bone Marrow Transplant; 2001 Feb; 27(3):287-93. PubMed ID: 11277176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment.
    Glück S; Ross AA; Layton TJ; Ostrander AB; Goldstein LC; Porter K; Ho AD
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):316-23. PubMed ID: 9502299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer.
    Bessho A; Ueoka H; Kiura K; Tabata M; Sunami K; Katayama Y; Yamane H; Hiraki A; Harada M
    Anticancer Res; 1999; 19(1B):693-8. PubMed ID: 10216478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High dosage therapy and autologous peripheral stem cell transplantation in breast carcinoma].
    Kier P; Ruckser R; Buxhofer V; Habertheuer KH; Zelenka P; Tatzreiter G; Hübl G; Kittl E; Hauser A; Sebesta C; Hinterberger W
    Acta Med Austriaca Suppl; 2000; 52():33-6. PubMed ID: 11261276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occult tumor cells detected in autologous blood stem cell harvests have no impact on 5 year outcomes for breast cancer patients with 4-9 positive nodes treated with adjuvant high-dose therapy and stem cell transplantation.
    Reed E; Kessinger A; Murphy B; Tarantolo S; Traystman M; Sharp JG
    Bone Marrow Transplant; 2003 Apr; 31(7):571-4. PubMed ID: 12692623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy.
    Vredenburgh JJ; Peters WP; Rosner G; DeSombre K; Johnston WW; Kamel A; Wu K; Bast RC
    Bone Marrow Transplant; 1995 Dec; 16(6):815-21. PubMed ID: 8750275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.